bioMerieux (OTCMKTS:BMXMF) Stock Crosses Below Fifty Day Moving Average – What’s Next?

bioMerieux (OTCMKTS:BMXMF) crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $92.82 and traded as low as $84.0750. bioMerieux shares last traded at $84.0750, with a volume of 6 shares changing hands.

Analyst Upgrades and Downgrades

BMXMF has been the topic of a number of recent analyst reports. Zacks Research raised shares of bioMerieux to a “hold” rating in a research report on Tuesday, April 28th. UBS Group lowered shares of bioMerieux from a “buy” rating to a “neutral” rating in a research report on Monday. Finally, Deutsche Bank Aktiengesellschaft lowered shares of bioMerieux from a “buy” rating to a “hold” rating in a research report on Friday, April 24th. Four investment analysts have rated the stock with a Hold rating, According to MarketBeat.com, bioMerieux presently has a consensus rating of “Hold”.

bioMerieux Stock Performance

The company has a current ratio of 2.39, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08. The business’s 50-day moving average is $92.82 and its two-hundred day moving average is $110.81.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.